Evidence map›Paper›PMID 39573933›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

γδ T Cell-mediated Tumor Immunity is Tightly Regulated by STING and TGF-β Signaling Pathways.

Jing Luo, Shengli Wang, Quanli Yang, Qianqian Fu, Chuyun Zhu, Tao Li, Shuxian Yang, Yin Zhao, Rong Guo, Xiaosong Ben and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Mechanisms and Applications of γδ T Cells in Anti-Tumor Immunity.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Jing LuoGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Shengli WangGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Quanli YangGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Qianqian FuGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Chuyun ZhuGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Tao LiGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Shuxian YangGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Yin ZhaoDepartment of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China.
Rong GuoDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, P. R. China.
Xiaosong BenDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, P. R. China.
Yuzhen ZhengDepartment of Pediatrics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, P. R. China.
Sitao LiDepartment of Pediatrics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, P. R. China.
Guang YangDepartment of Pathogen biology, School of Medicine, Jinan University, Guangzhou, 510632, P. R. China.
Hongru ZhangNankai International Advanced Research Institute, College of Life Sciences, Nankai University, Tianjin, 300071, P. R. China.
Hui XiaoShanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, 200031, P. R. China.
Zhengfan JiangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.
Nan YanDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Dieter KabelitzInstitute of Immunology, University of Kiel and University Hospital Schleswig-Holstein Campus Kiel, 24105, Kiel, Germany.
Guodong SunGuangdong Provincial Key Laboratory of Spine and Spinal Cord Reconstruction, The Fifth Affiliated Hospital of Jinan University, Heyuan, 517000, P. R. China.
Zvi GranotDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University Medical School, Ein Kerem, Jerusalem, 9112102, Israel.
Ligong LuGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.
Fuping YouDepartment of Immunology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, P. R. China.
Jianlei HaoGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.ORCID 0000-0003-4600-3082
Zhinan YinGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, 519000, P. R. China.ORCID 0000-0001-6524-8777

Funding

Department of Science and Technology of Henan Province 231111311300Deutsche Forschungsgemeinschaft 502/19-3Guangdong Basic and the 111 Project B16021National Key Research and Development Program of China 2020YFA0803502National Natural Science Foundation of China 31830021National Natural Science Foundation of China 32030036National Natural Science Foundation of China 32200708National Natural Science Foundation of China 32270980National Natural Science Foundation of China 32370921Natural Science Foundation of Hubei Province of China 2022CFB175Open Fund of Guangdong Provincial Key Laboratory of Laboratory of Spine and Spinal Cord Reconstruction 2023B121203001
6 · The paper itself

Abstract

The STING pathway plays a critical role in tumor immunosurveillance. However, the precise mechanisms by which STING regulates gamma delta (γδ) T cell function during tumor progression remain unclear. Herein, we find that tumor-derived cyclic GMP-AMP (cGAMP) activates a distinct STING pathway by inducing TBK1-mediated phosphorylation of Eomes in γδ T cells during the early stage of tumor development is demonstrated. This activation leads to interferon-gamma (IFN-γ) production and consequent tumor surveillance. However, at advanced stages of tumor progression, the accumulation of immune-suppressive cytokine transforming growth factor-beta (TGF-β) downregulates STING levels, compromising the function of γδ T cells. Notably, the synergism between TGF-β inhibition and STING agonists effectively counteracts the immunosuppressive tumor microenvironment, thereby augmenting the antitumoral effects of γδ T cells. These findings present a novel mechanism involving STING-mediated IFN-γ production in γδ T cells and hold significant implications for the development of potent immunotherapeutic approaches against cancer.

Indexed as

Membrane ProteinsNeoplasmsReceptors, Antigen, T-Cell, gamma-deltaSignal TransductionT-LymphocytesTransforming Growth Factor betaAnimalsHumansInterferon-gammaMiceMice, Inbred C57BLSTING ProteinTumor MicroenvironmentInterferon-gammaMembrane ProteinsReceptors, Antigen, T-Cell, gamma-deltaSTING1 protein, humanSting1 protein, mouseSTING ProteinTransforming Growth Factor betaEomesIFN‐γSTINGtumor immunityγδ T cells

Identifiers

PMID39573933
PMCPMC11727375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.